RARC with intracorporeal urinary diversion offers survival outcomes similar to those of open radical cystectomy, but is associated with better perioperative outcomes. Real-world data support the ...

Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...

Radical cystectomy involves bladder removal and urinary diversion, often using a laparoscopic robot-assisted approach for precision and access. The surgery lasts four to six hours, with a recovery ...

Radical cystectomy continues to have an important role in the management of recurrent high-grade NMIBC, according to results from the CISTO study. The CISTO study assessed patient-important outcomes ...

Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association.

—A retrospective real-world study of patients with muscle-invasive bladder cancer showed that robot-assisted and laparoscopic radical cystectomy reduce post-surgical complication rates, compared to ...

Platelet-to-lymphocyte ratio as a useful biomarker of recurrence and mortality risks in patients with muscle-invasive bladder cancer who achieved ypT0 to neoadjuvant chemotherapy: A multicenter ...

In a significant development for the field of oncology, ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced positive results from its clinical trials focused on treating bladder cancer. This ...

Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that exceeded 70% in a phase II study, but failed to meet prespecified ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...